-
1.NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE 审中-公开
Title translation: 新型双相羟肟酸盐作为组胺脱乙酰酶的抑制剂公开(公告)号:WO03066579A2
公开(公告)日:2003-08-14
申请号:PCT/US0303846
申请日:2003-02-07
Applicant: AXYS PHARMACEUTICALS , LEAHY ELLEN M , VERNER ERIK J
Inventor: LEAHY ELLEN M , VERNER ERIK J
IPC: C07D295/18 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/40 , A61K31/404 , A61K31/4045 , A61K31/4164 , A61K31/4184 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/495 , A61K31/5375 , A61K45/00 , A61P25/14 , A61P35/00 , A61P43/00 , C07C259/10 , C07C275/42 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07D207/16 , C07D209/14 , C07D209/18 , C07D209/42 , C07D211/10 , C07D211/16 , C07D211/22 , C07D211/30 , C07D211/46 , C07D211/60 , C07D211/62 , C07D213/38 , C07D213/56 , C07D213/65 , C07D213/81 , C07D213/82 , C07D233/54 , C07D233/64 , C07D235/18 , C07D295/108 , C07D295/135 , C07D307/24 , C07D307/68 , C07D317/58 , C07D317/60 , C07D317/68 , C07D333/24 , C07D333/38 , C07D401/12 , C07D405/12 , C12Q1/34 , C12Q1/37 , C12Q1/48 , C07C259/00
CPC classification number: C07D213/81 , C07C259/10 , C07C275/42 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07D207/16 , C07D209/14 , C07D209/16 , C07D209/18 , C07D211/16 , C07D211/22 , C07D211/46 , C07D211/60 , C07D211/62 , C07D213/38 , C07D213/56 , C07D213/65 , C07D213/82 , C07D233/64 , C07D235/18 , C07D295/108 , C07D295/135 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/58 , C07D317/60 , C07D317/68 , C07D333/24 , C07D333/38 , C07D405/12 , C12Q1/34 , C12Q1/37 , C12Q1/48 , G01N2333/974 , G01N2333/976
Abstract: The present invention is directed to certain bicyclic hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed
Abstract translation: 本发明涉及作为组蛋白脱乙酰酶的抑制剂的某些双环肟酸盐衍生物,因此可用于治疗与组蛋白脱乙酰酶活性相关的疾病。 还公开了制备这些化合物的药物组合物和方法
-
2.(HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS 审中-公开
Title translation: (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES,他们的制备及其作为蛋白酶抑制剂的用途公开(公告)号:WO0035886A3
公开(公告)日:2000-10-26
申请号:PCT/US9930302
申请日:1999-12-17
Applicant: AXYS PHARM INC , ALLEN DARIN ARTHUR , HATAYE JASON M , HRUZEWICZ WITOLD N , KOLESNIKOV ALEKSANDR , MACKMAN RICHARD LAURENCE , RAI ROOPA , SPENCER JEFFREY R , VERNER ERIK J , YOUNG WENDY B
Inventor: ALLEN DARIN ARTHUR , HATAYE JASON M , HRUZEWICZ WITOLD N , KOLESNIKOV ALEKSANDR , MACKMAN RICHARD LAURENCE , RAI ROOPA , SPENCER JEFFREY R , VERNER ERIK J , YOUNG WENDY B
IPC: A61K31/40 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/415 , A61K31/4184 , A61K31/425 , A61K31/427 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/5377 , A61K31/541 , A61K31/66 , A61P7/02 , A61P9/00 , A61P9/10 , A61P13/12 , A61P35/00 , A61P43/00 , C07D209/12 , C07D209/14 , C07D209/18 , C07D235/18 , C07D235/20 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D405/12 , C07D407/10 , C07D407/12 , C07D409/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D519/00 , C07F9/09
CPC classification number: C07D401/10 , C07D209/12 , C07D209/18 , C07D235/18 , C07D235/20 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D405/12 , C07D407/10 , C07D407/12 , C07D409/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04
Abstract: The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.
Abstract translation: 本发明提供新的式(I)化合物:AB,其前药形式或其药学上可接受的盐,其中A表示饱和的,不饱和的或部分不饱和的双环杂环结构,B表示芳基或杂芳基 组。 本发明优选的化合物包括苯并咪唑或吲哚核。 本发明的化合物是丝氨酸蛋白酶,尿激酶(uPA),因子Xa(FXa)和/或因子VIIa(FVIIa)的抑制剂,并且可用作抗癌剂和/或抗凝剂用于治疗或预防血栓栓塞 哺乳动物疾病。
-